M. Inoue

Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics

H. Yamanaka, K. Nishikawa, T. Takeuchi, 2021, Modern Rheumatology.

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates

H. Chikuda, Y. Yonemoto, K. Okamura, 2019, Journal of Experimental Orthopaedics.

Short-term daily teriparatide in patients with rheumatoid arthritis

H. Chikuda, Y. Yonemoto, K. Okamura, 2018, Modern rheumatology.

Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13

H. Chikuda, Y. Yonemoto, H. Inoue, 2022, BMC Rheumatology.

Evaluation of Kampo medicines used to treat rheumatoid arthritis in collagen-induced arthritic and pX transgenic mice

Y. Iwakura, S. Saijo, Y. Ogihara, 2003, Modern rheumatology.

Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.

A. Munakata, T. Muto, K. Kobayashi, 1995, Journal of gastroenterology.

Olsalazine in active ulcerative colitis: dose finding study in Japan.

A. Munakata, M. Kondo, M. Inoue, 1988, Scandinavian journal of gastroenterology. Supplement.

A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon α-2b and ribavirin

N. Ogata, K. Soga, T. Watanabe, 2006, Gut.

Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab

Y. Saeki, H. Yamanaka, Yoshiya Tanaka, 2017, Modern rheumatology.

[A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin for chronic hepatitis C].

N. Ogata, K. Soga, K. Shibasaki, 2006, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.